{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2014:PKZPIZC4M3KVIBHJQLNYXUWVBK","short_pith_number":"pith:PKZPIZC4","canonical_record":{"source":{"id":"1402.2643","kind":"arxiv","version":2},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-02-06T17:16:51Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"6ba0aed236779e7801b1ff5739c3fc1755df4534b9d97266f71678443e190146","abstract_canon_sha256":"6c5a10924c28f29db49ee9af5f39dd8904460c4034a869ae97c0bf644f665984"},"schema_version":"1.0"},"canonical_sha256":"7ab2f4645c66d55404e982db8bd2d50aaf7ed62d3090aab698bdba9953b24cd2","source":{"kind":"arxiv","id":"1402.2643","version":2},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1402.2643","created_at":"2026-05-18T01:20:21Z"},{"alias_kind":"arxiv_version","alias_value":"1402.2643v2","created_at":"2026-05-18T01:20:21Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1402.2643","created_at":"2026-05-18T01:20:21Z"},{"alias_kind":"pith_short_12","alias_value":"PKZPIZC4M3KV","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_16","alias_value":"PKZPIZC4M3KVIBHJ","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_8","alias_value":"PKZPIZC4","created_at":"2026-05-18T12:28:43Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2014:PKZPIZC4M3KVIBHJQLNYXUWVBK","target":"record","payload":{"canonical_record":{"source":{"id":"1402.2643","kind":"arxiv","version":2},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-02-06T17:16:51Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"6ba0aed236779e7801b1ff5739c3fc1755df4534b9d97266f71678443e190146","abstract_canon_sha256":"6c5a10924c28f29db49ee9af5f39dd8904460c4034a869ae97c0bf644f665984"},"schema_version":"1.0"},"canonical_sha256":"7ab2f4645c66d55404e982db8bd2d50aaf7ed62d3090aab698bdba9953b24cd2","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T01:20:21.326895Z","signature_b64":"J7Gn25ViD6yqdXtE488iUIWTJqjxyKZwSnvi4gQNRHKePGX6aUmYiyCkLgeQzhYQjfXkuEKlsC4oon2UPKldCg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"7ab2f4645c66d55404e982db8bd2d50aaf7ed62d3090aab698bdba9953b24cd2","last_reissued_at":"2026-05-18T01:20:21.326255Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T01:20:21.326255Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1402.2643","source_version":2,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T01:20:21Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"7hXzlAhpyWa/YlXpyReK8bL+2bmEJ7d4R5aHbJsU3BUg1ykepzSdcB8GIbUB+dYwi1OSrjybIbNJG0S1G2N+Bw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-25T23:30:39.738565Z"},"content_sha256":"b92c57656a1d032a85459c1cd050f4d60ee6b43e90d736649385260b36498897","schema_version":"1.0","event_id":"sha256:b92c57656a1d032a85459c1cd050f4d60ee6b43e90d736649385260b36498897"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2014:PKZPIZC4M3KVIBHJQLNYXUWVBK","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"q-bio.QM","authors_text":"Armin D. Goralczyk, Christian R\\\"over, Nicola D. Crins, Tim Friede","submitted_at":"2014-02-06T17:16:51Z","abstract_excerpt":"Interleukin-2 receptor antagonists (IL-2RA) are frequently used as induction therapy in liver transplant recipients to decrease the risk of acute rejection while allowing the reduction of concomitant immunosuppression. The exact association with the use of IL-2RA however is uncertain. We performed a systematic literature search for relevant studies. Random effects models were used to assess the incidence of acute rejection, steroid-resistant rejection, graft loss, patient death, and adverse drug reaction, with or without IL-2RA. Six studies (2 randomized and 4 nonrandomized) met the elegibilit"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1402.2643","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T01:20:21Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"kqIFAuKmgTzo+TI3rVRYXCeQYGzwgVh2kdjr4ZOQt77V1TlcYeSPwy6kfWaQGjtKvo708gcj2C4bYip479QsBA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-25T23:30:39.739294Z"},"content_sha256":"1b150e8df0000643d8448a27af79557e46a7da949650b76fdac86946680bb2d5","schema_version":"1.0","event_id":"sha256:1b150e8df0000643d8448a27af79557e46a7da949650b76fdac86946680bb2d5"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK/bundle.json","state_url":"https://pith.science/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-25T23:30:39Z","links":{"resolver":"https://pith.science/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK","bundle":"https://pith.science/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK/bundle.json","state":"https://pith.science/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK/state.json","well_known_bundle":"https://pith.science/.well-known/pith/PKZPIZC4M3KVIBHJQLNYXUWVBK/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2014:PKZPIZC4M3KVIBHJQLNYXUWVBK","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"6c5a10924c28f29db49ee9af5f39dd8904460c4034a869ae97c0bf644f665984","cross_cats_sorted":["stat.AP"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-02-06T17:16:51Z","title_canon_sha256":"6ba0aed236779e7801b1ff5739c3fc1755df4534b9d97266f71678443e190146"},"schema_version":"1.0","source":{"id":"1402.2643","kind":"arxiv","version":2}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1402.2643","created_at":"2026-05-18T01:20:21Z"},{"alias_kind":"arxiv_version","alias_value":"1402.2643v2","created_at":"2026-05-18T01:20:21Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1402.2643","created_at":"2026-05-18T01:20:21Z"},{"alias_kind":"pith_short_12","alias_value":"PKZPIZC4M3KV","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_16","alias_value":"PKZPIZC4M3KVIBHJ","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_8","alias_value":"PKZPIZC4","created_at":"2026-05-18T12:28:43Z"}],"graph_snapshots":[{"event_id":"sha256:1b150e8df0000643d8448a27af79557e46a7da949650b76fdac86946680bb2d5","target":"graph","created_at":"2026-05-18T01:20:21Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Interleukin-2 receptor antagonists (IL-2RA) are frequently used as induction therapy in liver transplant recipients to decrease the risk of acute rejection while allowing the reduction of concomitant immunosuppression. The exact association with the use of IL-2RA however is uncertain. We performed a systematic literature search for relevant studies. Random effects models were used to assess the incidence of acute rejection, steroid-resistant rejection, graft loss, patient death, and adverse drug reaction, with or without IL-2RA. Six studies (2 randomized and 4 nonrandomized) met the elegibilit","authors_text":"Armin D. Goralczyk, Christian R\\\"over, Nicola D. Crins, Tim Friede","cross_cats":["stat.AP"],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-02-06T17:16:51Z","title":"Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1402.2643","kind":"arxiv","version":2},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:b92c57656a1d032a85459c1cd050f4d60ee6b43e90d736649385260b36498897","target":"record","created_at":"2026-05-18T01:20:21Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"6c5a10924c28f29db49ee9af5f39dd8904460c4034a869ae97c0bf644f665984","cross_cats_sorted":["stat.AP"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-02-06T17:16:51Z","title_canon_sha256":"6ba0aed236779e7801b1ff5739c3fc1755df4534b9d97266f71678443e190146"},"schema_version":"1.0","source":{"id":"1402.2643","kind":"arxiv","version":2}},"canonical_sha256":"7ab2f4645c66d55404e982db8bd2d50aaf7ed62d3090aab698bdba9953b24cd2","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"7ab2f4645c66d55404e982db8bd2d50aaf7ed62d3090aab698bdba9953b24cd2","first_computed_at":"2026-05-18T01:20:21.326255Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T01:20:21.326255Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"J7Gn25ViD6yqdXtE488iUIWTJqjxyKZwSnvi4gQNRHKePGX6aUmYiyCkLgeQzhYQjfXkuEKlsC4oon2UPKldCg==","signature_status":"signed_v1","signed_at":"2026-05-18T01:20:21.326895Z","signed_message":"canonical_sha256_bytes"},"source_id":"1402.2643","source_kind":"arxiv","source_version":2}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:b92c57656a1d032a85459c1cd050f4d60ee6b43e90d736649385260b36498897","sha256:1b150e8df0000643d8448a27af79557e46a7da949650b76fdac86946680bb2d5"],"state_sha256":"6608db7dab1f7ca52677f619fcf399cd1e9bd6c58efcd6bcce1dbeaf0f895e30"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"+OKgFDPmpjtXaAQAyO9AHVp/8hq99gBsx29d4eOQnHZIXgI1WrVLfxVtDPa8wem82CC/VXS2HN8pYZTw/oKoCg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-25T23:30:39.743074Z","bundle_sha256":"92c01a1a14a8a7e2fe864ea2600fdba5bb82e653e1fa2046d01269f4374b2f32"}}